药物开发过程:提高效率和成本效益 328条(本栏目收费,不能显示细节,电话13136136841)
Models neutral networks, 245-246 246
physiological systems, 241-244 244
Monoclonal antibodies (MoAbs), 188 188
Neural networks, 245-246 246
New Drug Application (NDA), 33-35, 83 83
Nicotine Transdermal Systems, 184 184
Nonclinical development, 272-273 273
Novel drug delivery systems, 9, 170-192 192
System Response Correlation Concept, 118, 161-167 167
Targeted therapy, 187-190 190
Tools for Structure Activity Relationships (TSAR), 223 223
Total Quality Management (TQM) techniques, 96 96
Toxicokinetics, 251, 266 266
Transdermal drug delivery, 176-179 179
Wickline liability, 64 64
Central laboratory, 384, 395-400 400
establishing in Europe, 399-400 400
operational pretrial checks at, 412-414 414
Clinical pathology and clinical trials, 380-381 381
laboratories, 384-386 386